Publications in collaboration with researchers from Clínica Universitaria de Navarra (16)

2025

  1. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

    Journal of Clinical Oncology

  2. Correction to: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes (Nature Genetics, (2024), 56, 9, (1878-1889), 10.1038/s41588-024-01853-0)

    Nature Genetics

  3. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

    HemaSphere, Vol. 9, Núm. 4

  4. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

    Journal of Clinical Oncology

  5. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

2024

  1. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

  2. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  3. Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients

    HemaSphere, Vol. 8, Núm. 12

  4. High-risk cytogenetic abnormalities in multiple myeloma: PETHEMA-GEM experience

    HemaSphere, Vol. 8, Núm. 12

  5. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

2017

  1. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

    Haematologica, Vol. 102, Núm. 1, pp. 168-175

2016

  1. Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma

    American Journal of Pathology, Vol. 186, Núm. 8, pp. 2171-2182

2015

  1. Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1849, Núm. 3, pp. 353-366

  2. Myeloma

    UICC Manual of Clinical Oncology, Ninth Edition (wiley), pp. 415-426

2008

  1. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia

    British Journal of Haematology, Vol. 142, Núm. 4, pp. 571-582

  2. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression

    Haematologica, Vol. 93, Núm. 4, pp. 560-565